Head-to-head evidence
PBF-1129 vs TT-4
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: Adenosine A2b receptor · full Non-Small Cell Lung Cancer pipeline
PBF-1129
Developed by Palobiofarma SL
NCT03274479 · Phase 1 · status unknown
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
TT-4
Developed by AlphaTON Capital Corp.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2028 · NCT04969315 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: PBF-1129's landscape · TT-4's landscape